METTL3 and hepatocellular carcinoma: To verify the role of METTL3 in mediating sorafenib resistance in HCC progression, we first performed a syngeneic xenograft mouse model in C57BL/6 mice with Hepa1‐6 engineered with a METTL3 knockout by CRISPR/Cas9 (Appendix Fig S5G) and drug administration with two regimens: DMSO and sorafenib (50 mg/kg every 2 days, intraperitoneally).